Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture
Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese populationCurr Med Res Opin. 2011 Jun;27(6):1141-8. doi: 10.1185/03007995.2011.570747. Epub 2011 Apr 1
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Seven randomized controlled trials were included in this meta-analysis which investigated the use of oral bisphosphonates (etidronate, alendronate, or risendronate) in the prevention of hip fracture in the population suffering from neurological diseases, such as amylotrophic lateral sclerosis, stroke, or Parkinson's disease. Included studies were placebo controlled with the exception of one, which...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE